Cost-effectiveness analysis of combination therapies involving novel agents for first/second-relapse patients with multiple myeloma: a Markov model approach with calibration techniques
Although this study did not fully account for the heterogeneity of subsequent treatment regimens among first/second-relapse MM patients, it highlights that the substantial financial burden associated with combination therapies involving novel agents poses a significant challenge in justifying their economic value.
Authors
- Zixuan Zhao (ORCID: https://orcid.org/0000-0002-1254-1504)
- Hengjin Dong (ORCID: https://orcid.org/0000-0002-5064-7297)
- Yannan Wang (ORCID: https://orcid.org/0000-0001-7248-4954)
- Weijia Wu (ORCID: https://orcid.org/0000-0003-3912-7212)
- Yuan Gao (ORCID: https://orcid.org/0000-0001-9561-7852)
- Wenqianzi Yang
- Fan Tang (ORCID: https://orcid.org/0000-0002-3975-2483)
Institutions
- Fudan University (CN)
- Pudong Medical Center (CN)
- Zhejiang Provincial People's Hospital (CN)
- Hangzhou Medical College (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Health Economics Review
- Published
- 2025-03-15
- DOI
- https://doi.org/10.1186/s13561-025-00611-0
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- China Scholarship Council
- Zhejiang Pharmaceutical Association